FDA Approves Adjuvant Pembrolizumab for Stage IB-IIIA NSCLC
Results from the phase 3 PEARLS/KEYNOTE-091 trial have led to the FDA approval of adjuvant pembrolizumab for the treatment fully resected NSCLC.
Related Articles
Clinical Presentation and Diagnosis of BPDCN
Dr. Schiller will discuss the key clinical and pathologic features that distinguish BPDCN from other malignancies, as well as the potential differential diagnoses that share…
Understanding Mutations and Targeted Treatments in Thyroid Cancer
Lova Sun, MD, MCSE, discussed genetic mutations in thyroid cancer and how they impact clinicians’ treatment options.
Steroid-Refractory cGvHD: Emerging Treatment Options
This segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the…
Renal Cell Carcinoma: Risk Stratification and Evolving Treatment Landscape
A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.
FDA Calls for Boxed Warnings for CAR T-Cell Immunotherapies
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
Creating Solutions for a ‘Continual State of Transition’ in Cancer Care
In a Peers & Perspectives in Oncology feature article, we focus on the importance of the transition-of-care process for patients with cancer as they move…
Adjuvant Pembrolizumab Offers Improved OS in KEYNOTE-564 Trial of ccRCC
Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a…
Lower Net Worth Linked to Higher Costs Post Bladder Cancer Treatment
For patients who underwent radical cystectomy for bladder cancer, those with lower net worth incurred higher costs posttreatment.
Diagnosis and Initial Management of cGVHD
This segment focuses on the key considerations for diagnosing cGvHD and the initial treatment approaches, including the use of corticosteroids and combination therapies. The discussion…
Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC
Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.